Delphine L Chen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2466563/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Positron emission tomography with [18F]fluorodeoxyglucose to evaluate neutrophil kinetics during acute lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2004, 286, L834-L840.	2.9	103
2	Quantifying Pulmonary Inflammation in Cystic Fibrosis with Positron Emission Tomography. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1363-1369.	5.6	91
3	FDG-PET imaging of pulmonary inflammation in healthy volunteers after airway instillation of endotoxin. Journal of Applied Physiology, 2006, 100, 1602-1609.	2.5	76
4	Synthesis, [18F] radiolabeling, and evaluation of poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors for in vivo imaging of PARP-1 using positron emission tomography. Bioorganic and Medicinal Chemistry, 2014, 22, 1700-1707.	3.0	64
5	Chemokine Receptor 2–targeted Molecular Imaging in Pulmonary Fibrosis. A Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 78-89.	5.6	61
6	[18F]Fluorodeoxyglucose Positron Emission Tomography for Lung Antiinflammatory Response Evaluation. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 533-539.	5.6	57
7	PET of Poly (ADP-Ribose) Polymerase Activity in Cancer: Preclinical Assessment and First In-Human Studies. Radiology, 2017, 282, 453-463.	7.3	57
8	Quantification of Lung PET Images: Challenges and Opportunities. Journal of Nuclear Medicine, 2017, 58, 201-207.	5.0	55
9	Imaging Caspase-3 Activation as a Marker of Apoptosis-Targeted Treatment Response in Cancer. Molecular Imaging and Biology, 2015, 17, 384-393.	2.6	49
10	Design and Synthesis of 2-Amino-4-methylpyridine Analogues as Inhibitors for Inducible Nitric Oxide Synthase and in Vivo Evaluation of [¹⁸ F]6-(2-Fluoropropyl)-4-methyl-pyridin-2-amine as a Potential PET Tracer for Inducible Nitric Oxide Synthase. Journal of Medicinal Chemistry, 2009, 52, 2443-2453.	6.4	48
11	Long-range function of secreted small nucleolar RNAs that direct 2′-O-methylation. Journal of Biological Chemistry, 2018, 293, 13284-13296.	3.4	48
12	Imaging Pulmonary Inflammation with Positron Emission Tomography:  A Biomarker for Drug Development. Molecular Pharmaceutics, 2006, 3, 488-495.	4.6	44
13	Molecular imaging of lung glucose uptake after endotoxin in mice. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2005, 289, L760-L768.	2.9	43
14	Imaging Pulmonary Inducible Nitric Oxide Synthase Expression with PET. Journal of Nuclear Medicine, 2015, 56, 76-81.	5.0	41
15	Comparison of methods to quantitate 18F-FDG uptake with PET during experimental acute lung injury. Journal of Nuclear Medicine, 2004, 45, 1583-90.	5.0	41
16	Comparison of radiolabeled isatin analogs for imaging apoptosis with positron emission tomography. Nuclear Medicine and Biology, 2009, 36, 651-658.	0.6	40
17	Imaging Pulmonary Inflammation. Journal of Nuclear Medicine, 2016, 57, 1764-1770.	5.0	28
18	PET imaging approaches for inflammatory lung diseases: Current concepts and future directions. European Journal of Radiology, 2017, 86, 371-376.	2.6	23

Delphine L Chen

#	Article	IF	CITATIONS
19	An obligatory role for club cells in preventing obliterative bronchiolitis in lung transplants. JCI Insight, 2019, 4, .	5.0	23
20	Radiolabeled isatin binding to caspase-3 activation induced by anti-Fas antibody. Nuclear Medicine and Biology, 2012, 39, 137-144.	0.6	22
21	Advances in Positron Emission Tomographic Imaging of Lung Cancer. Proceedings of the American Thoracic Society, 2005, 2, 541-544.	3.5	20
22	Multimodality molecular imaging of the lung. Journal of Magnetic Resonance Imaging, 2010, 32, 1409-1420.	3.4	17
23	Update 2018. Clinical Nuclear Medicine, 2018, 43, e439-e452.	1.3	15
24	FDG PET Imaging in Cystic Fibrosis. Seminars in Nuclear Medicine, 2013, 43, 412-419.	4.6	13
25	Synthesis and evaluation of 18F-labeled PPARÎ ³ antagonists. Nuclear Medicine and Biology, 2012, 39, 77-87.	0.6	12
26	Failure of Cyclosporin A to Rescue Peripheral Nerve Allografts in Acute Rejection. Annals of Plastic Surgery, 2002, 49, 660-667.	0.9	11
27	PET imaging of in vivo caspase-3/7 activity following myocardial ischemia-reperfusion injury with the radiolabeled isatin sulfonamide analogue [(18)F]WC-4-116. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 110-9.	1.0	11
28	Neutrophils and Neutrophil Products Do Not Mediate Pulmonary Hemodynamic Effects of Endotoxin on Oleic Acid-Induced Lung Injury. Anesthesia and Analgesia, 2004, 98, 452-457.	2.2	8
29	Consensus Recommendations on the Use of 18F-FDG PET/CT in Lung Disease. Journal of Nuclear Medicine, 2020, 61, 1701-1707.	5.0	8
30	Selective Imaging of Lung Macrophages Using [11C]PBR28-Based Positron Emission Tomography. Molecular Imaging and Biology, 2021, 23, 905-913.	2.6	8
31	Molecular imaging for pediatric lung diseases. Pediatric Pulmonology, 2004, 37, 286-296.	2.0	7
32	The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study. PLoS ONE, 2018, 13, e0191783.	2.5	7
33	Glypican-3 targeted delivery of 89Zr and 90Y as a theranostic radionuclide platform for hepatocellular carcinoma. Scientific Reports, 2021, 11, 3731.	3.3	7
34	Glypican-3–Targeted ²²⁷ Th α -Therapy Reduces Tumor Burden in an Orthotopic Xenograft Murine Model of Hepatocellular Carcinoma. Journal of Nuclear Medicine, 2022, 63, 1033-1038.	5.0	7
35	Automated production of a sphingosine-1 phosphate receptor 1 (S1P1) PET radiopharmaceutical [11C]CS1P1 for human use. Applied Radiation and Isotopes, 2019, 152, 30-36.	1.5	6
36	Concurrent Pembrolizumab with AVD for Untreated Classical Hodgkin Lymphoma. Blood, 2021, 138, 233-233.	1.4	6

Delphine L Chen

#	Article	IF	CITATIONS
37	Pain responses in patients with upper-extremity disorders. Journal of Hand Surgery, 1998, 23, 954-955.	1.6	5
38	Molecular Imaging of Enzyme Function in Lungs. Methods in Enzymology, 2004, 385, 315-333.	1.0	4
39	Radiologic Assessment of Groin Lymph Nodes in Pelvic Malignancies. International Journal of Gynecological Cancer, 2020, 30, 947-953.	2.5	4
40	How Accurately does PSMA Inhibitor 18F-DCFPyL-PET-CT Image Prostate Cancer?. Clinical Cancer Research, 2021, 27, 3512-3514.	7.0	4
41	Overview of positron emission tomography in functional imaging of the lungs for diffuse lung diseases. British Journal of Radiology, 2022, 95, 20210824.	2.2	3
42	The Development of ¹⁸ F Fluorthanatrace: A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1. Radiology Imaging Cancer, 2022, 4, e210070.	1.6	3
43	Multimodality molecular imaging of the lung. Clinical and Translational Imaging, 2014, 2, 391-401.	2.1	2
44	Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia on Somatostatin Receptor Imaging. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1223-1225.	5.6	2
45	PET Imaging of PARP Expression Using 18F-Olaparib. Journal of Nuclear Medicine, 2019, 60, 502-503.	5.0	2
46	Promising Advances for Imaging Lung Macrophage Recruitment. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 11-13.	5.6	2
47	Title is missing!. Journal of Hand Surgery, 1998, 23, 953-954.	1.6	0
48	Prognostic value of early FDG PET response imaging and peripheral immunologic biomarkers: sub-study of a phase II trial of risk-adaptive chemoradiation for unresectable non-small cell lung cancer. Advances in Radiation Oncology, 2021, 7, 100857.	1.2	0